Floatz logo

Gip

Metabolic Bone Disorder

Esbjerg Hospital - University Hospital of Southern Denmarkprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Metabolic Bone Disorder cohort.

Asset / SponsorPhaseRating
VITAMIN D
University of Sao Paulo General Hospital
Phase 4BB
Biktarvy
Saskatchewan Health Authority - Regina Area
Phase 4BB
Genvoya
Saskatchewan Health Authority - Regina Area
Phase 4BB
Epclusa
Saskatchewan Health Authority - Regina Area
Phase 4BB
ALENDRONIC ACID
McMaster University
Phase 4BB

Same molecule, other indications

Gip is also rated in:

fatty liver diseaseActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
type 2 diabetes mellitusActive
CCC
Indicative · Phase 1
48 / 100
View asset →
metabolic dysfunction-associated steatohepatitisActive
CC
Indicative · Phase 1/2
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →